Tearsheet
NTRB Home Investment Highlights Valuation, Metrics & Events Price Chart Why The Stock Moved Return vs. Risk About NTRB Interactive Breakdown Better Bets vs. NTRB Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Trade Sentinel Industry Resource Links External Quote Links

Nutriband (NTRB)

Market Price (3/15/2026): $3.71 | Market Cap: $44.7 Mil
Sector: Health Care | Industry: Biotechnology

Nutriband (NTRB)

Market Price (3/15/2026): $3.71
Market Cap: $44.7 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11%		 Weak multi-year price returns
3Y Excs Rtn is -74%		 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -9.3 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -406%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -36%		  Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -46%
2 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, Targeted Therapies, Show more.		  Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 153%
3   Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -248%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -248%
4   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -33%
5   Significant short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 20.73
0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -36%
2 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, Targeted Therapies, Show more.
3 Weak multi-year price returns
3Y Excs Rtn is -74%
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -9.3 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -406%
5 Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -46%
6 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 153%
7 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -248%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -248%
8 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -33%
9 Significant short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 20.73

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Nutriband (NTRB) stock has lost about 25% since 11/30/2025 because of the following key factors:

1. Continued Financial Losses and Limited Cash Runway: Nutriband reported increasing annual losses of -$10.48 million in fiscal year 2025, marking a 91.1% increase from 2024, despite a modest 2.60% increase in revenue to $2.14 million. This financial position is considered a major risk, with the company having less than one year of cash runway.

2. Absence of Definitive AVERSA Fentanyl Regulatory Milestones: Although Nutriband provided updates on its AVERSA Fentanyl patch development in late January 2026, including a strengthened partnership and a Type C meeting with the FDA, there were no announcements of definitive FDA approvals or major positive clinical trial results during the specified period. The market is awaiting future events such as an Investigational New Drug (IND) application filing and the initiation of clinical studies in 2026.

Show more

Stock Movement Drivers

Fundamental Drivers

The -24.6% change in NTRB stock from 11/30/2025 to 3/13/2026 was primarily driven by a -11.6% change in the company's Total Revenues ($ Mil).
(LTM values as of)113020253132026Change
Stock Price ($)4.953.73-24.6%
Change Contribution By: 
Total Revenues ($ Mil)32-11.6%
P/S Multiple21.519.7-8.3%
Shares Outstanding (Mil)1112-7.0%
Cumulative Contribution-24.6%

LTM = Last Twelve Months as of date shown

Market Drivers

11/30/2025 to 3/13/2026
ReturnCorrelation
NTRB-24.6% 
Market (SPY)-3.1%2.6%
Sector (XLV)-5.0%-0.8%

Fundamental Drivers

The -42.3% change in NTRB stock from 8/31/2025 to 3/13/2026 was primarily driven by a -34.2% change in the company's P/S Multiple.
(LTM values as of)83120253132026Change
Stock Price ($)6.463.73-42.3%
Change Contribution By: 
Total Revenues ($ Mil)22-5.0%
P/S Multiple30.019.7-34.2%
Shares Outstanding (Mil)1112-7.7%
Cumulative Contribution-42.3%

LTM = Last Twelve Months as of date shown

Market Drivers

8/31/2025 to 3/13/2026
ReturnCorrelation
NTRB-42.3% 
Market (SPY)3.0%14.1%
Sector (XLV)9.5%6.2%

Fundamental Drivers

The -48.7% change in NTRB stock from 2/28/2025 to 3/13/2026 was primarily driven by a -50.6% change in the company's P/S Multiple.
(LTM values as of)22820253132026Change
Stock Price ($)7.273.73-48.7%
Change Contribution By: 
Total Revenues ($ Mil)2212.7%
P/S Multiple39.919.7-50.6%
Shares Outstanding (Mil)1112-7.9%
Cumulative Contribution-48.7%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2025 to 3/13/2026
ReturnCorrelation
NTRB-48.7% 
Market (SPY)12.4%15.9%
Sector (XLV)1.9%12.2%

Fundamental Drivers

The -6.5% change in NTRB stock from 2/28/2023 to 3/13/2026 was primarily driven by a -35.3% change in the company's Shares Outstanding (Mil).
(LTM values as of)22820233132026Change
Stock Price ($)3.993.73-6.5%
Change Contribution By: 
Total Revenues ($ Mil)2211.5%
P/S Multiple15.219.729.6%
Shares Outstanding (Mil)812-35.3%
Cumulative Contribution-6.5%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2023 to 3/13/2026
ReturnCorrelation
NTRB-6.5% 
Market (SPY)73.4%11.0%
Sector (XLV)23.3%12.9%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
NTRB Return-6%-58%-36%103%-4%-13%-57%
Peers Return-11%-36%104%25%32%7%105%
S&P 500 Return27%-19%24%23%16%-1%80%

Monthly Win Rates [3]
NTRB Win Rate17%33%50%50%33%33% 
Peers Win Rate42%38%62%50%58%67% 
S&P 500 Win Rate75%42%67%75%67%33% 

Max Drawdowns [4]
NTRB Max Drawdown-71%-72%-46%-1%-14%-13% 
Peers Max Drawdown-24%-47%-27%-9%-26%-0% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-2% 

[1] Cumulative total returns since the beginning of 2021
[2] Peers: VTRS, AMRX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/13/2026 (YTD)

How Low Can It Go

Unique KeyEventNTRBS&P 500
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-40.0%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven66.7%51.3%
2020 Covid PandemicTime to BreakevenTime to BreakevenNot Fully Recovered days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-75.3%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven305.1%24.7%
2018 CorrectionTime to BreakevenTime to BreakevenNot Fully Recovered days120 days

Compare to VTRS, AMRX

In The Past

Nutriband's stock fell -40.0% during the 2020 Covid Pandemic from a high on 3/6/2020. A -40.0% loss requires a 66.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Nutriband (NTRB)

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.

AI Analysis | Feedback

Imagine them as the **Insulet** (known for its Omnipod insulin pump) of pain patches, focused on developing innovative transdermal systems for safer drug delivery.

They're a specialized pharmaceutical R&D company, like a focused, early-stage division of **Johnson & Johnson** or **Pfizer**, but solely dedicated to creating advanced, abuse-deterrent drug patches for chronic pain.

AI Analysis | Feedback

```html
  • Abuse deterrent fentanyl transdermal system: An extended-release transdermal fentanyl product designed for managing chronic pain while deterring abuse.
  • RAMBAM Closed System Transfer Devices: Medical devices for safely transferring substances, developed under a license agreement.
```

AI Analysis | Feedback

Nutriband Inc. (NTRB) is a clinical-stage pharmaceutical company focused on developing transdermal drug products and medical devices. Based on the provided background information, the company's lead product, an abuse-deterrent fentanyl transdermal system, is currently in development. The RAMBAM Closed System Transfer Devices, developed under a license agreement with Rambam Med-Tech Ltd., are also in development.

As a development-stage company, Nutriband Inc. does not currently have major commercial customers for the sale of its pharmaceutical products or devices, as these products are not yet commercially available on the market. Pharmaceutical development companies typically focus on research, development, clinical trials, and securing regulatory approvals before initiating commercial sales and establishing a customer base.

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

Better Bets vs. Nutriband (NTRB)

Latest Trefis Analyses

TitleDate
0DASHBOARDS 
1Can Nutriband Stock Recover If Markets Fall?10/17/2025
Title
0ARTICLES

Trade Ideas

Select ideas related to NTRB.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
QDEL_2282026_Insider_Buying_45D_2Buy_200K02282026QDELQuidelOrthoInsiderInsider Buys 45DStrong Insider Buying
Companies with multiple insider buys in the last 45 days		0.0%0.0%0.0%
CHE_2272026_Dip_Buyer_FCFYield02272026CHEChemedDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		0.0%0.0%0.0%
LLY_2272026_Monopoly_xInd_xCD_Getting_Cheaper02272026LLYEli LillyMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		0.0%0.0%0.0%
HAE_2202026_Dip_Buyer_FCFYield02202026HAEHaemoneticsDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		3.5%3.5%0.0%
IQV_2132026_Dip_Buyer_ValueBuy02132026IQVIQVIADip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		7.1%7.1%-3.0%

Recent Active Movers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Peers to compare with:

Financials

NTRBVTRSAMRXMedian
NameNutribandViatris Amneal P. 
Mkt Price3.7313.5111.8311.83
Mkt Cap0.015.63.73.7
Rev LTM214,3003,0193,019
Op Inc LTM-9254398254
FCF LTM-61,851226226
FCF 3Y Avg-52,040241241
CFO LTM-62,316340340
CFO 3Y Avg-42,506327327

Growth & Margins

NTRBVTRSAMRXMedian
NameNutribandViatris Amneal P. 
Rev Chg LTM12.7%-3.0%8.0%8.0%
Rev Chg 3Y Avg3.9%-4.2%11.0%3.9%
Rev Chg Q-46.4%5.0%11.5%5.0%
QoQ Delta Rev Chg LTM-11.6%1.2%2.9%1.2%
Op Mgn LTM-406.5%1.8%13.2%1.8%
Op Mgn 3Y Avg-313.5%5.6%11.9%5.6%
QoQ Delta Op Mgn LTM-142.4%-0.9%0.9%-0.9%
CFO/Rev LTM-247.6%16.2%11.3%11.3%
CFO/Rev 3Y Avg-208.1%16.9%12.1%12.1%
FCF/Rev LTM-247.9%12.9%7.5%7.5%
FCF/Rev 3Y Avg-210.7%13.7%9.0%9.0%

Valuation

NTRBVTRSAMRXMedian
NameNutribandViatris Amneal P. 
Mkt Cap0.015.63.73.7
P/S19.71.11.21.2
P/EBIT-3.5-4.99.8-3.5
P/E-3.5-4.451.6-3.5
P/CFO-8.06.710.96.7
Total Yield-28.4%-19.0%1.9%-19.0%
Dividend Yield0.0%3.6%0.0%0.0%
FCF Yield 3Y Avg-12.8%14.6%11.1%11.1%
D/E0.00.90.70.7
Net D/E-0.10.80.60.6

Returns

NTRBVTRSAMRXMedian
NameNutribandViatris Amneal P. 
1M Rtn-13.5%-15.5%-19.5%-15.5%
3M Rtn-26.9%17.0%-3.1%-3.1%
6M Rtn-47.8%38.4%18.3%18.3%
12M Rtn-39.1%57.5%34.6%34.6%
3Y Rtn15.8%56.9%727.3%56.9%
1M Excs Rtn-11.1%-13.1%-17.1%-13.1%
3M Excs Rtn-22.1%19.1%-1.5%-1.5%
6M Excs Rtn-49.0%32.7%14.4%14.4%
12M Excs Rtn-62.4%32.0%12.2%12.2%
3Y Excs Rtn-73.9%-23.3%534.4%-23.3%

Comparison Analyses

null

Financials

Segment Financials

Assets by Segment
$ Mil20252024202320222021
Pocono Pharmaceuticals556  
4P Therapeutics222  
Corporate225  
Total10913  


Price Behavior

Price Behavior
Market Price$3.73 
Market Cap ($ Bil)0.0 
First Trading Date03/16/2018 
Distance from 52W High-65.2% 
   50 Days200 Days
DMA Price$4.36$6.14
DMA Trenddowndown
Distance from DMA-14.5%-39.2%
 3M1YR
Volatility70.4%82.2%
Downside Capture218.49171.85
Upside Capture57.8187.16
Correlation (SPY)3.6%14.9%
NTRB Betas & Captures as of 2/28/2026

 1M2M3M6M1Y3Y
Beta1.110.190.050.930.670.75
Up Beta-0.11-1.23-1.44-0.79-0.180.15
Down Beta3.45-1.54-1.181.240.690.63
Up Capture43%49%72%53%119%121%
Bmk +ve Days9203170142431
Stock +ve Days11213056114348
Down Capture114%230%142%168%141%106%
Bmk -ve Days12213054109320
Stock -ve Days10203167130378

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with NTRB
NTRB-25.9%79.6%-0.06-
Sector ETF (XLV)5.0%17.5%0.1211.6%
Equity (SPY)19.6%18.9%0.8114.4%
Gold (GLD)71.9%26.3%2.05-0.7%
Commodities (DBC)19.3%17.3%0.89-2.0%
Real Estate (VNQ)6.2%16.3%0.1917.5%
Bitcoin (BTCUSD)-15.3%44.2%-0.2512.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with NTRB
NTRB-2.8%131.7%0.48-
Sector ETF (XLV)7.5%14.5%0.3311.6%
Equity (SPY)13.1%17.0%0.6110.8%
Gold (GLD)24.1%17.3%1.141.3%
Commodities (DBC)11.2%19.0%0.470.5%
Real Estate (VNQ)4.8%18.8%0.167.8%
Bitcoin (BTCUSD)6.3%56.7%0.335.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with NTRB
NTRB31.3%226.1%0.81-
Sector ETF (XLV)10.1%16.5%0.508.0%
Equity (SPY)14.5%17.9%0.708.3%
Gold (GLD)14.4%15.6%0.771.5%
Commodities (DBC)8.6%17.6%0.40-0.2%
Real Estate (VNQ)5.6%20.7%0.235.8%
Bitcoin (BTCUSD)67.4%66.8%1.070.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date2272026
Short Interest: Shares Quantity0.2 Mil
Short Interest: % Change Since 21520264.9%
Average Daily Volume0.0 Mil
Days-to-Cover Short Interest20.7 days
Basic Shares Quantity12.1 Mil
Short % of Basic Shares1.7%

Returns Analyses

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
SUMMARY STATS   
# Positive000
# Negative000
Median Positive   
Median Negative   
Max Positive   
Max Negative   

SEC Filings

Expand for More
Report DateFiling DateFiling
10/31/202512/11/202510-Q
07/31/202509/09/202510-Q
04/30/202505/30/202510-Q
01/31/202504/28/202510-K
10/31/202412/04/202410-Q
07/31/202409/03/202410-Q
04/30/202405/31/202410-Q
01/31/202405/01/202410-K
10/31/202312/13/202310-Q
07/31/202309/11/202310-Q
04/30/202306/09/202310-Q
01/31/202304/26/202310-K
10/31/202212/02/202210-Q
07/31/202209/08/202210-Q
04/30/202205/31/202210-Q
01/31/202204/29/202210-K

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.